rosa
sgv
santo
wc
clinic
trial
drug
reposit
treatment
rev
panam
salud
publica
abstract
world
health
organ
inform
decemb
coronaviru
pneumonia
outbreak
wuhan
hubei
provinc
china
subsequ
march
case
death
report
coronaviru
envelop
rna
viru
genu
betacoronaviru
distribut
bird
human
mammal
name
novel
coronaviru
diseas
clinic
trial
launch
test
coronaviru
treatment
includ
drug
repurpos
reposit
henc
perform
search
march
clinicaltrialsgov
databas
elig
criteria
retriev
studi
contain
clinicaltrialsgov
base
identifi
number
describ
number
particip
period
studi
describ
particip
clinic
condit
util
intervent
medicin
alreadi
studi
approv
diseas
patient
infect
novel
coronaviru
essenti
emphas
articl
captur
trial
list
clinicaltrialsgov
databas
identifi
clinic
trial
involv
medicin
human
immunoglobulin
interferon
chloroquin
hydroxychloroquin
arbidol
remdesivir
favipiravir
lopinavir
ritonavir
oseltamivir
methylprednisolon
bevacizumab
tradit
chines
medicin
tcm
although
drug
repurpos
limit
reposit
clinic
trial
may
repres
attract
strategi
facilit
discoveri
new
class
medicin
lower
cost
take
less
time
reach
market
exist
pharmaceut
suppli
chain
formul
distribut
world
health
organ
inform
decemb
pneumonia
outbreak
wuhan
hubei
provinc
china
citi
million
inhabit
march
case
death
nearli
case
report
novel
coronaviru
name
coronaviru
later
renam
sever
acut
respiratori
syndrom
coronaviru
name
novel
coronaviru
diseas
confirm
case
countri
territori
outsid
china
includ
japan
unit
state
america
itali
iran
brazil
coronaviru
envelop
rna
viru
genu
betacoronaviru
distribut
bird
human
mammal
new
evid
indic
link
bat
coronaviru
six
speci
coronaviru
known
infecti
human
four
caus
common
cold
symptom
howev
author
claim
even
relat
coronaviru
speci
respons
sever
acut
respiratori
syndrom
sarscov
well
middl
east
respiratori
syndrom
merscov
zoonot
origin
link
sever
signific
ill
higher
mortal
exampl
juli
report
sarscov
case
especi
china
hong
kong
relat
death
concern
merscov
june
april
peopl
infect
countri
case
saudi
arabia
death
unfortun
vaccin
medicin
approv
novel
coronaviru
infect
clinic
trial
launch
test
coronaviru
treatment
includ
drug
repurpos
reposit
drug
reposit
neglect
diseas
essenti
univers
strategi
develop
new
drug
due
lower
cost
reduc
time
reach
market
clinic
trial
step
might
requir
especi
concern
phase
ii
b
exist
pharmaceut
suppli
chain
avail
formul
distribut
c
possibl
combin
drug
treatment
effect
monotherapi
may
facilit
discoveri
new
mechan
action
old
drug
new
class
medicin
hand
repurpos
strategi
limit
includ
patent
barrier
complex
regulatori
pathway
absenc
fund
opportun
greater
access
data
industrysponsor
clinic
trial
heterogen
popul
new
clinic
studi
nevertheless
drug
repurpos
still
tool
discoveri
entir
new
class
medicin
henc
consid
scenario
felt
interest
awar
drug
reposit
clinic
test
treatment
perform
search
march
clinicaltri
gov
databas
descriptor
coronaviru
simpl
search
field
condit
diseas
search
without
restrict
languag
diseas
condit
result
locat
elig
criteria
retriev
studi
contain
clinicaltrialsgov
base
identifi
number
describ
number
particip
studi
period
describ
patient
clinic
condit
intervent
util
medicin
alreadi
studi
approv
diseas
patient
clinicaltrialsgov
resourc
us
nation
librari
medicin
contain
clinic
studi
conduct
countri
identifi
clinic
trial
tabl
studi
clinic
phase
pharmaceut
intervent
found
treatment
includ
human
immunoglobulin
interferon
chloroquin
hydroxychloroquin
arbidol
remdesivir
oseltamivir
favipiravir
carrimycin
methylprednisolon
bevacizumab
thalidomid
vitamin
c
pirfenidon
bromhexin
fingolimod
danoprevir
ritonavir
darunavir
cobicistat
lopinavir
xiyanp
tradit
chines
medicin
tcm
chloroquin
hydroxychloroquin
antimalari
drug
antivir
effect
human
immunodefici
viru
hiv
name
inhibit
viru
entri
host
cell
anoth
antivir
mechan
relat
posttransl
alter
newli
synthes
protein
via
glycosyl
inhibit
hydroxychloroquin
alreadi
use
clinic
trial
acquir
immun
defici
syndrom
aid
treatment
recent
trial
patient
treatment
patient
treat
hydroxychloroquin
combin
macrolid
antibiot
azithromycin
virolog
cure
compar
patient
treat
hydroxychloroquin
alon
control
group
current
chloroquin
hydroxychloroquin
test
patient
pneumonia
caus
chloroquin
prevent
medicin
shown
tabl
immunoglobulin
use
sever
diseas
idiopath
thrombocytopenia
purpura
itp
guillainbarr
syndrom
gb
chronic
inflammatori
demyelin
polyneuropathi
cidp
kawasaki
diseas
multipl
neurolog
autoimmun
disord
refractori
standard
immunosuppress
treatment
broadli
neutral
antibodi
recogn
wide
varieti
glycoprotein
gp
viru
surfac
protein
shell
nonenvelop
viru
howev
dengu
viru
denv
influenza
virus
hepat
c
viru
hcv
ebola
viru
ebov
mutat
superfici
gp
order
evad
antibodi
respons
obstacl
develop
new
therapi
infect
trial
util
human
immunoglobulin
patient
pneumonia
caus
tabl
two
clinic
studi
refer
use
remdesivir
sever
mild
respiratori
infect
remdesivir
nucleotid
analog
inhibitor
ebov
rnapolymeras
rnadepend
rdrp
dyer
et
al
describ
preliminari
find
mortal
rate
patient
treat
remdesivir
ebov
diseas
earli
infect
stage
author
note
mortal
rate
almost
peopl
nontreat
infect
patient
epidem
period
wang
et
al
present
data
show
remdesivir
effect
vero
cell
ec
suggest
mechan
remdesivir
involv
host
cell
postentri
stage
arbidol
also
known
umifenovir
approv
russia
china
treatment
influenza
viru
infect
signific
advers
effect
patent
sar
treatment
shown
tabl
four
clinic
trial
conduct
treatment
one
arbidol
comparison
basic
treatment
three
studi
compar
effect
oseltamivir
lopinavirritonavir
carrimycin
arbidol
antivir
mechan
influenza
b
involv
viral
fusion
inhibit
target
membran
block
viru
entri
cell
oseltamivir
anoth
drug
approv
influenza
b
treatment
inhibit
viral
neuraminidas
consequ
block
releas
viral
particl
host
cell
reduc
spread
respiratori
tract
addit
use
oseltamivir
alreadi
report
epidem
china
either
without
antibiot
corticosteroid
oseltamivir
also
use
clinic
trial
multipl
combin
chloroquin
favipiravir
nucleosid
analog
wellknown
broadspectrum
antivir
drug
shown
ec
low
toxic
lopinavirritonavir
combin
approv
aid
treatment
sever
countri
drug
hiv
proteas
inhibitor
ritonavir
also
cytochrom
gp
inhibitor
fact
endors
lopinavir
pharmacokinet
pharmacodynam
activ
hiv
combin
plu
interferon
phase
mer
treatment
sever
trial
involv
lopinavirritonavir
treatment
comparison
use
drug
carrimycin
tcm
xiyanp
danoprevirritonavir
interferon
inhal
nevertheless
one
previou
articl
argu
clinic
trial
patient
laboratoryconfirm
infect
lopinavirritonavir
combin
associ
clinic
improv
compar
standard
care
procedur
carrimycin
macrolid
antibiot
effect
gramposit
bacteria
vitro
effect
mycobacterium
tuberculosi
danoprevir
hcv
proteas
inhibitor
approv
china
treatment
noncirrhot
genotyp
chronic
hepat
c
combin
ritonavir
peginterferona
ribavirin
tradit
chines
medicin
tcm
use
phytotherapeut
formul
tea
pill
powder
tinctur
cultur
compon
origin
year
ago
chines
medicin
tcm
alreadi
use
sarscov
infect
coadjuv
therapi
enhanc
patient
symptom
increas
oxyhemoglobin
arteri
satur
prove
use
earli
stage
infect
interferon
ifn
protein
bind
cellular
surfac
receptor
initi
jakstat
signal
cascad
transcript
regul
gene
control
interferon
effect
virus
like
hepat
b
viru
hcv
xiyanp
tcm
prepar
andrographolid
princip
compon
signific
antibacteri
antivir
effect
darunavir
combin
cobicistat
use
trial
number
patient
pneumonia
unit
state
food
drug
administr
fda
current
approv
combin
aid
treatment
darunavir
anoth
hiv
proteas
inhibitor
cobicistat
like
ritonavir
booster
enhanc
pharmacokinet
pharmacodynam
darunavir
cytochrom
inhibit
recombin
human
interferon
describ
inhibitori
effect
merscov
sarscov
purpos
clinic
trial
found
paper
evalu
efficaci
safeti
recombin
human
interferon
treat
patient
new
coronaviru
infect
thalidomid
use
two
trial
thalidomid
antiinflammatori
action
due
abil
speed
degrad
messeng
rna
blood
cell
thu
reduc
tumor
necrosi
factora
tnfa
furthermor
thalidomid
increas
secret
interleukin
activ
natur
killer
cell
corticosteroid
methylprednisolon
test
long
et
al
report
corticosteroid
therapi
methylprednisolon
dexamethason
hydrocortison
benefici
treat
sarscov
patient
significantli
prolong
surviv
time
clinic
case
nevertheless
author
describ
use
corticosteroid
earli
stage
sar
infect
increas
valu
viral
load
furthermor
studi
corticosteroid
adjuv
therapi
merscov
infect
unabl
prove
efficaci
patient
die
methylprednisolon
alreadi
use
patient
combin
antibiot
oseltamivir
oxygen
therapi
final
vitamin
c
ascorb
acid
pirfenidon
bevacizumab
fingolimod
bromhexin
hydrochlorid
go
test
vitamin
c
antioxid
activ
may
reduc
oxid
stress
inflamm
effect
improv
vasopressor
synthesi
enhanc
immun
cell
function
improv
endovascular
function
provid
epigenet
immunolog
modif
clinic
trial
demonstr
promis
data
mortal
improv
sepsi
extens
studi
necessari
valid
conclus
pirfenidon
use
treatment
idiopath
pulmonari
fibrosi
diseas
due
antiinflammatori
antioxid
effect
name
inhibit
trial
claim
antiinflammatori
effect
may
help
infect
bevacizumab
human
monoclon
antibodi
target
vascular
endotheli
growth
factor
vegf
may
reduc
level
vegf
caus
hypoxia
sever
inflamm
upregul
infect
respiratori
tract
epithelium
might
suppress
edema
patient
fingolimod
receptor
regul
effect
immunolog
modul
use
multipl
sclerosi
accord
patholog
find
pulmonari
edema
hyalin
membran
format
use
immun
modul
togeth
ventil
support
consid
sever
patient
prevent
develop
acut
respiratori
distress
syndrom
ard
studi
aim
determin
efficaci
fingolimod
bromhexin
transmembran
proteas
serin
inhibitor
proteas
respons
activ
sglycoprotein
sarscov
merscov
viral
entri
plasma
membran
one
studi
evalu
efficaci
bromhexin
combin
standard
treatmentstandard
treatment
patient
conclus
declar
epidem
pneumonia
caus
review
found
clinic
trial
alreadi
start
reposit
medicin
treatment
human
immunoglobulin
interferon
chloroquin
hydroxychloroquin
arbidol
remdesivir
favipiravir
oseltamivir
thalidomid
methylprednisolon
bevacizumab
tcm
hydroxychloroquineazithromycin
combin
first
drug
repurpos
excel
result
clinic
trial
extend
studi
higher
number
patient
need
confirm
result
besid
limit
reposit
clinic
trial
still
attract
strategi
may
facilit
discoveri
new
class
medicin
may
reduc
cost
time
reach
market
exist
pharmaceut
suppli
chain
formul
distribut
possibl
combin
drug
treatment
effect
monotherapi
studi
found
articl
schedul
end
hope
reposit
trial
may
help
find
solut
treatment
year
disclaim
author
hold
sole
respons
view
express
manuscript
may
necessarili
reflect
opinion
polici
rpsppajph
andor
paho
